We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
Read MoreHide Full Article
Key Takeaways
Janux is advancing JANX007 and JANX014 in prostate cancer, with more JANX007 data expected in 2027.
JANX011 expands Janux's pipeline into autoimmune diseases, with initial clinical data expected in late 2026.
Janux ended Q2 2026 with $970.9 million in cash, equivalents and short-term investments.
Shares of Janux Therapeutics (JANX - Free Report) have risen 19.1% over the past three months, driven by continued progress across its clinical pipeline and a series of upcoming catalysts.
The company is making steady progress across its oncology and immunotherapy pipeline, led by its three proprietary tumor-activated core platforms, including Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr) and Adaptive Immune Response Modulator (ARM). The company’s pipeline comprises several wholly owned assets, notably JANX007, JANX014, JANX011 and JANX013.
Year to date, JANX shares have risen 25.3% compared with the industry’s 12.9% growth.
Image Source: Zacks Investment Research
Progress Across Prostate Cancer Programs
Janux’s lead prostate cancer candidate, JANX007, remains a major driver of investor interest. The prostate-specific membrane antigen (PSMA)-targeted TRACTr is being evaluated in a phase Ib study in metastatic castration-resistant prostate cancer (mCRPC), with continued enrollment, dose optimization and expansion in taxane-naïve patients. The company is evaluating JANX007 in combination with darolutamide to improve outcomes in earlier-stage mCRPC patients. Additional data on JANX007 is expected in the first half of 2027. This combination strategy could broaden the potential clinical utility of JANX007 and strengthen its positioning within the competitive prostate cancer treatment landscape.
In April, the company initiated patient dosing in a phase I study evaluating JANX014, a next-generation double-masked PSMA TRACTr program designed to enhance tumor selectivity and safety in prostate cancer.
Autoimmune Pipeline Creates a Second Growth Opportunity
Beyond oncology, Janux is expanding into autoimmune diseases with JANX011, a CD19-targeted ARM. The candidate is currently being evaluated in an early-stage clinical study in healthy volunteers, with dosing underway. The company expects to provide initial clinical data from the study in the second half of 2026.
The company continues to advance additional TRACTr, TRACIr and ARM programs for potential future development. Janux intends to begin clinical development of JANX013, a PSMA-targeted CD28 costimulatory TRACIr candidate, later in 2026. The candidate is designed to be administered in combination with JANX007.
Beyond these wholly owned pipeline candidates, Janux has strategic collaborations with Merck & Co. (MRK - Free Report) and Bristol Myers Squibb (BMY - Free Report) to develop novel tumor-activated therapies using the TRACTr platform. Under the agreement with BMY, the companies are expected to develop a novel, tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types.
Janux initiated patient dosing in its TRACTr collaboration program with MRK (known as MSD outside the United States and Canada) in August 2025 and remains eligible for future milestone payments and royalties tied to the program’s development and commercialization.
Strong Balance Sheet Reduces Financing Risk
JANX ended the second quarter of 2026 with $970.9 million in cash, cash equivalents and short-term investments. At the same time, the company's quarterly net loss narrowed substantially year over year due to lower operating expenses. The combination of a large cash balance and lower quarterly losses give Janux considerable flexibility to continue investing in its clinical programs.
View the Zacks #1 Rank List
Image: Bigstock
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
Key Takeaways
Shares of Janux Therapeutics (JANX - Free Report) have risen 19.1% over the past three months, driven by continued progress across its clinical pipeline and a series of upcoming catalysts.
The company is making steady progress across its oncology and immunotherapy pipeline, led by its three proprietary tumor-activated core platforms, including Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr) and Adaptive Immune Response Modulator (ARM). The company’s pipeline comprises several wholly owned assets, notably JANX007, JANX014, JANX011 and JANX013.
Year to date, JANX shares have risen 25.3% compared with the industry’s 12.9% growth.
Image Source: Zacks Investment Research
Progress Across Prostate Cancer Programs
Janux’s lead prostate cancer candidate, JANX007, remains a major driver of investor interest. The prostate-specific membrane antigen (PSMA)-targeted TRACTr is being evaluated in a phase Ib study in metastatic castration-resistant prostate cancer (mCRPC), with continued enrollment, dose optimization and expansion in taxane-naïve patients. The company is evaluating JANX007 in combination with darolutamide to improve outcomes in earlier-stage mCRPC patients. Additional data on JANX007 is expected in the first half of 2027. This combination strategy could broaden the potential clinical utility of JANX007 and strengthen its positioning within the competitive prostate cancer treatment landscape.
In April, the company initiated patient dosing in a phase I study evaluating JANX014, a next-generation double-masked PSMA TRACTr program designed to enhance tumor selectivity and safety in prostate cancer.
Autoimmune Pipeline Creates a Second Growth Opportunity
Beyond oncology, Janux is expanding into autoimmune diseases with JANX011, a CD19-targeted ARM. The candidate is currently being evaluated in an early-stage clinical study in healthy volunteers, with dosing underway. The company expects to provide initial clinical data from the study in the second half of 2026.
The company continues to advance additional TRACTr, TRACIr and ARM programs for potential future development. Janux intends to begin clinical development of JANX013, a PSMA-targeted CD28 costimulatory TRACIr candidate, later in 2026. The candidate is designed to be administered in combination with JANX007.
Beyond these wholly owned pipeline candidates, Janux has strategic collaborations with Merck & Co. (MRK - Free Report) and Bristol Myers Squibb (BMY - Free Report) to develop novel tumor-activated therapies using the TRACTr platform. Under the agreement with BMY, the companies are expected to develop a novel, tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types.
Janux initiated patient dosing in its TRACTr collaboration program with MRK (known as MSD outside the United States and Canada) in August 2025 and remains eligible for future milestone payments and royalties tied to the program’s development and commercialization.
Strong Balance Sheet Reduces Financing Risk
JANX ended the second quarter of 2026 with $970.9 million in cash, cash equivalents and short-term investments. At the same time, the company's quarterly net loss narrowed substantially year over year due to lower operating expenses. The combination of a large cash balance and lower quarterly losses give Janux considerable flexibility to continue investing in its clinical programs.
Janux Therapeutics, Inc. Price and Consensus
Janux Therapeutics, Inc. price-consensus-chart | Janux Therapeutics, Inc. Quote
JANX's Zacks Rank
Janux currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.